HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James M. Donahue Francis C. Nichols Mark S. Allen Stephen D. Cassivi Aminah Jatoi Robert C. Miller Dennis A. Wigle Claude Deschamps Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donahue, J. M. Articles by Deschamps, C. Search for Related Content PubMed PubMed Citation Articles by Donahue, J. M. Articles by Deschamps, C. Related Collections Esophagus - cancer

---

Original Articles: General Thoracic

Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival

^a Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota
^b Division of Biostatistics, Mayo Clinic, Rochester, Minnesota
^c Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
^d Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota

Accepted for publication November 3, 2008.

^_* Address correspondence to Dr Nichols, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905 (Email: nichols.francis{at}mayo.edu).

Presented at the Fifty-fourth Annual Meeting of the Southern Thoracic Surgical Association, Bonita Springs, FL, Nov 7–10, 2007.

Background: Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach.

Methods: From January 1998 through December 2003, all patients from a single institution receiving neoadjuvant chemoradiotherapy followed by esophagogastrectomy were reviewed for operative mortality, morbidity, long-term survival, and factors affecting survival. Only patients preoperatively staged with both computed tomographic scans and endoscopic ultrasound were included.

Results: There were 162 patients (142 men, 20 women), and the median age was 61 years (range, 22 to 81 years). Histopathology was adenocarcinoma in 143 patients and squamous cell in 19. Pretreatment clinical stage was II in 28 patients (17%), III in 111 (68%), and IV (M1a) in 23 (14%). Ivor Lewis esophagogastrectomy was the most common procedure, occurring in 132 patients. Operative mortality and morbidity was 4.9% and 37%, respectively. Pathologic response was complete in 42 patients (26%), near complete in 27 (17%), partial in 88 (54%), and unresectable in 5 (3%). Five-year survival for overall, complete, near complete, and partial response patients was 34%, 55%, 27%, and 27%, respectively (p = 0.013). Patients whose lymph nodes were rendered free of cancer showed improved overall and disease-free survival compared with patients having persistently positive lymph nodes (p = 0.019).

Conclusions: Esophagogastrectomy after neoadjuvant chemoradiotherapy can be performed with low mortality and morbidity. Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses. Future efforts should be directed at understanding determinants of complete responses.

This article has been cited by other articles:

				B. M. Stiles, F. Mirza, A. Coppolino, J. L. Port, P. C. Lee, S. Paul, and N. K. Altorki Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Ann. Thorac. Surg., August 1, 2011; 92(2): 491 - 498. [Abstract] [Full Text] [PDF]

				J. A. Ajani, M. A. Blum, J. Welsh, W. L. Hofstetter, and S. G. Swisher Celebrate or Calibrate? We Say Calibrate J. Clin. Oncol., July 1, 2011; 29(19): 2732 - 2732. [Full Text] [PDF]

				R. K. Singh, T. H. Pham, B. S. Diggs, S. Perkins, and J. G. Hunter Minimally Invasive Esophagectomy Provides Equivalent Oncologic Outcomes to Open Esophagectomy for Locally Advanced (Stage II or III) Esophageal Carcinoma Arch Surg, June 1, 2011; 146(6): 711 - 714. [Abstract] [Full Text] [PDF]

				A. M. Monjazeb, G. Riedlinger, M. Aklilu, K. R. Geisinger, G. Mishra, S. Isom, P. Clark, E. A. Levine, and A. W. Blackstock Outcomes of Patients With Esophageal Cancer Staged With [18F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of Resection? J. Clin. Oncol., November 1, 2010; 28(31): 4714 - 4721. [Abstract] [Full Text] [PDF]

				K. R. Shen, K. M. Harrison-Phipps, S. D. Cassivi, D. Wigle, F. C. Nichols III, M. S. Allen, C. M. Wood, and C. Deschamps Esophagectomy after anti-reflux surgery. J. Thorac. Cardiovasc. Surg., April 1, 2010; 139(4): 969 - 975. [Abstract] [Full Text] [PDF]

				S. C. Tomaszek, S. D. Cassivi, M. S. Allen, K. R. Shen, F. C. Nichols III, C. Deschamps, and D. A. Wigle An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy, Eur J Cardiothorac Surg, April 1, 2010; 37(4): 807 - 813. [Abstract] [Full Text] [PDF]

				B. M. Stiles, P. Christos, J. L. Port, P. C. Lee, S. Paul, J. Saunders, and N. K. Altorki Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer J. Thorac. Cardiovasc. Surg., February 1, 2010; 139(2): 387 - 394. [Abstract] [Full Text] [PDF]